Article

Novel treatment found for LHON

A novel treatment for Leber’s hereditary optic neuropathy (LHON) uses a modified virus to introduce healthy genes into the mitochondria to correct the genetic defect.

Miami-A novel treatment for Leber’s hereditary optic neuropathy (LHON) uses a modified virus to introduce healthy genes into the mitochondria to correct the genetic defect.

No cure exists for LHON. Using experimental models, however, a team led by John Guy, MD, has shown that it is safe and effective to replace mutated genes with healthy ones and that doing so can prevent deterioration of the retinal cells that form the optic nerve. To deliver the healthy genes into the mitochondria, researchers redirected the adeno-associated virus to the mitochondria rather than to its typical target, the nucleus.

“This new approach shows the vast potential for genetic-therapy applications while helping to address a significant cause of blindness,” said Dr. Guy, a professor of ophthalmology at Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine. Aging, cancer, and Parkinson’s disease also are caused by mutations in the mitochondria, he added.

This research demonstrates that when efficiently introduced into mitochondria, it is possible for normal DNA to correct a biochemical defect in cellular energy production and restore visual function. The investigators’ next steps will be to try incorporating all three genes that cause LHON into a single viral carrier. Dr. Guy hopes to receive FDA approval to inject therapeutic genes into patients who have visual loss from mitochondrial disease.

Two National Institutes of Health/National Eye Institute grants totaling $6.1 million funded this research, which began in 2007. Proceedings of the National Academy of Sciences published an article by Dr. Guy about the research on April 20. The article is available at www.pnas.org/content/early/2012/04/19/1119577109.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.